The Global Alzheimer’s Platform Foundation enrolled 1,000+ participants with unprecedented 28% from traditionally understudied populations
Washington D.C., August 11, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) has reached full enrollment for the innovative Bio-Hermes-002 Study, successfully recruiting more than 1,000 participants. The milestone marks an important step toward advancing the next generation of blood and digital biomarker tests that could help detect Alzheimer’s disease earlier, more accurately and more equitably.
Bio-Hermes-002 is evaluating how blood-based and digital biomarkers can help predict the presence of Alzheimer’s disease pathology across a broad range of racial and ethnic groups.
“GAP is proud to announce that enrollment is complete for Bio-Hermes-002. This study is essential for the development of tests that could be offered in a primary care setting, advancing access to diagnostics and treatment pathways for people who have faced barriers for far too long,” said GAP President John Dwyer. “With a focus on representation, we designed this study to be intentionally inclusive, demonstrating that clinical trials can successfully engage and enroll people from traditionally understudied and underserved populations. We thank the volunteers who are the unsung heroes in clinical research and allow us to advance the science needed to bring hope for all impacted by Alzheimer’s disease.”
Alzheimer’s disease does not affect all communities equally. People who are African American are twice as likely and people who are Hispanic are 1.5 times as likely to develop Alzheimer’s and related dementias compared to older white Americans. Yet these populations have been traditionally understudied in clinical research, often a percentage in the low single digits[1]. Bio-Hermes-002 was designed to help close the research gap by ensuring its findings are informed by participants who better reflect the real-world population affected by Alzheimer’s disease.
The study’s completion represents another milestone in the effort to accelerate the development of accessible, less invasive diagnostic tools. Blood-based biomarkers have the potential to make Alzheimer’s testing more widely available by reducing reliance on more expensive and invasive procedures, helping connect people to appropriate care and research opportunities earlier in the course of disease.
The successful enrollment in the Bio-Hermes-002 study was made possible by the commitment of study volunteers and the collaboration of research sites across the GAP-Net network. The study has also been a collaborative effort uniquely comprised of industry leaders who are partners in this study, including AINOSTICS, Alamar Biosciences, Beckman Coulter Diagnostics, Biogen, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Eli Lilly and Company, Fujirebio, iLoF, IXICO, LifeArc, Linus Health, Lucent Diagnostics–a Quanterix brand, Retispec, Roche, Sanofi, Siemens Healthineers, Spear Bio, Taudia, and ViewMind.
For more information about the Bio-Hermes-002 study, visit Bio-Hermes-002.
About the Global Alzheimer’s Platform Foundation® (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US and Canada are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.
[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC13032159/#zoi260105t1